• Sulfamonomethoxine Toxicity in Aquatic Species: Insights & I

  2026-05-09

  This study systematically assesses the acute and chronic toxicity of sulfamonomethoxine (SMM), a veterinary sulfonamide antibiotic, across five representative aquatic organisms. The findings reveal pronounced species-specific sensitivity, with microalgae being most vulnerable, highlighting the need for careful environmental monitoring and experimental design in aquatic ecotoxicology.

• Canagliflozin: Mitochondrial Remodeling and New Horizons in

  2026-05-09

  This thought-leadership article explores the cutting-edge mechanistic and translational insights surrounding Canagliflozin, a potent SGLT2 inhibitor. It bridges emerging evidence on mitochondrial remodeling in diabetic kidney disease with actionable strategic guidance for translational researchers. By integrating recent animal model findings, workflow innovations, and protocol parameters, the piece positions APExBIO’s Canagliflozin as an essential tool for advancing metabolic and renal research beyond traditional glucose-centric endpoints.

• Molnupiravir Blocks Bourbon Virus in Mice: Antiviral Insight

  2026-05-08

  This study demonstrates that molnupiravir, an orally available nucleoside analogue, significantly inhibits Bourbon virus (BRBV) replication and disease in a mouse model. The findings highlight molnupiravir’s potential as a candidate for treating emerging tick-borne RNA viral infections, paving the way for translational antiviral research against BRBV.

• TMEM16F and Lipid Scrambling as Regulators of Ferroptosis in

  2026-05-07

  Yang et al. (2025) identify TMEM16F-mediated lipid scrambling as a critical suppressor of ferroptosis at the plasma membrane, revealing that its loss increases membrane vulnerability and triggers robust tumor immune rejection. These findings highlight a new axis for cancer therapy by targeting lipid scrambling to enhance ferroptotic cell death and immunogenicity.

• 2-APB: Precision Tool for Calcium Oscillation and Apoptosis

  2026-05-07

  2-APB (2-aminoethoxydiphenyl borate) from APExBIO is a benchmark inhibitor for dissecting intracellular calcium dynamics, enabling researchers to unravel autophagy-apoptosis transitions and ER-Ca2+ signaling in both cellular and organismal models. This guide delivers actionable workflow refinements, troubleshooting insights, and a synthesis of the latest reference breakthroughs for oxidative stress and programmed cell death research.

• Genistein in Cytoskeleton-Dependent Autophagy and Cancer Res

  2026-05-06

  Genistein enables precision dissection of cytoskeleton-mediated autophagy and growth factor signaling, setting a new standard for translational oncology workflows. This article translates the latest mechanistic breakthroughs into actionable protocols and troubleshooting strategies for researchers aiming to optimize cell-based assays and cancer chemoprevention studies.

• Cell Surface GlycoRNA–RBP Domains Facilitate Peptide Entry

  2026-05-06

  This study reveals that RNA binding proteins (RBPs) and glycoRNAs form specialized nanoclusters on the cell surface, which act as entry points for cell-penetrating peptides like TAT. These findings broaden the molecular landscape of the cell surface and provide mechanistic insight into how extracellular peptides and possibly pathogens interact with cells.

• Remdesivir (GS-5734): Optimizing Antiviral Workflows in Benc

  2026-05-05

  Leverage Remdesivir (GS-5734) for robust inhibition of viral RNA synthesis in coronavirus and Ebola virus research. This guide delivers workflow enhancements, troubleshooting strategies, and practical insights to maximize assay reproducibility and translational relevance.

• Ridaforolimus (Deforolimus, MK-8669): Reliable mTOR Inhibiti

  2026-05-05

  This article offers bench scientists a scenario-driven, data-backed guide to leveraging Ridaforolimus (Deforolimus, MK-8669) (SKU B1639) for robust cell viability, proliferation, and cytotoxicity assays. Addressing common workflow challenges, we explore protocol optimization, data interpretation, and vendor selection, grounding recommendations in published literature and validated parameters.

• Remdesivir (GS-5734): Reliable Antiviral Assay Solutions in

  2026-05-04

  This article provides scenario-driven guidance for biomedical researchers and laboratory scientists using Remdesivir (GS-5734) (SKU B8398) in cell viability, proliferation, and cytotoxicity assays. It addresses common experimental challenges—such as reproducibility and compound compatibility—by integrating rigorous data and vendor selection criteria, ensuring that researchers can confidently leverage Remdesivir's validated antiviral activity.

• FGF19–ELF4 Axis Drives Metastasis in Colorectal Cancer via F

  2026-05-04

  This study uncovers how FGF19-mediated upregulation of ELF4 promotes colorectal cancer (CRC) metastasis by transactivating FGFR4 and SRC. The work reveals a clinically relevant feedback loop, identifies ELF4 as an independent prognostic marker, and demonstrates the therapeutic potential of dual FGFR4/SRC inhibition for metastatic CRC.

• Tamoxifen Mechanisms: Translational Leverage in Breast Cance

  2026-05-03

  This article provides translational researchers with a deep mechanistic understanding of tamoxifen, a selective estrogen receptor modulator, and strategic insights for its use in breast cancer and gene knockout studies. Integrating recent evidence on caveolin-1 modulation and competitive agents like fucoidan, it contextualizes tamoxifen’s unique value in experimental design and therapeutic innovation.

• Meropenem in Resistance Dynamics: Deep Analysis & Assay Impa

  2026-05-02

  Explore Meropenem's role as a β-lactam antibiotic carbapenem in the context of real-world resistance dynamics, integrating the latest transmission data and advanced assay design. This article uniquely connects molecular findings to practical laboratory workflows.

• ML216: Catalyzing Synthetic Lethality in DNA Repair Research

  2026-05-02

  This thought-leadership article unpacks the mechanistic role of ML216, a BLM helicase inhibitor, in advancing synthetic lethality and DNA repair studies. We contextualize BLM helicase targeting within emerging paradigms in oncology, bridge recent findings from RecQ helicase research to translational workflows, and deliver strategic guidance for maximizing ML216's impact in preclinical models.

• N6-Methyl-dATP: Epigenetic Fidelity, Genomic Stability & AML

  2026-05-01

  Explore the multifaceted role of N6-Methyl-dATP in DNA replication fidelity, genomic stability, and acute myeloid leukemia (AML) research. This article offers a distinctive, science-driven analysis and practical guidance for epigenetic assays.

15983 records 1/1066 page Next 12345 下5页 Last page